Study how HIV multiplies during HIV drug treatment
Part of Infections clinical trials.
This study looks at how HIV continues to multiply (or stays suppressed) while you are taking antiretroviral therapy, using blood samples. It may help researchers better understand what HIV is doing during treatment and why some people experience changes like viral rebound.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have HIV, confirmed by standard blood test results (ELISA and Western blot).
- You were previously enrolled in one of two specific NIH studies, or you are already followed at NIH long-term and have stored samples that can be used.
- You must have stored samples taken before you started HIV treatment, if available.
- Your viral level (HIV “copies”) should be well controlled (under 50 copies/mL), OR it was under 50 copies/mL and later rose again while on treatment.
- You have a private physician who handles your usual ongoing medical care. (The study may still use additional study visits/sampling.)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This study tests how well researchers can track HIV-related health and immune changes over time by collecting blood and other samples. It may help you and your care team by creating detailed monitoring, even if your HIV diagnosis is new or still being evaluated.
This research study collects blood cells from people recently diagnosed with HIV who haven't started HIV medicines yet. Researchers use these samples to understand how HIV affects the immune system and develop better treatments.
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
This study looks at why some people with HIV on antiretroviral therapy still have small amounts of virus in their blood, while others achieve undetectable levels. Researchers will compare the two groups to understand the virus and immune system, which may help improve future treatments.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.